or
forgot password

Phase II Study to Evaluate the Efficacy of Trilogy Stereotactic Body Radiotherapy (SBRT) for Pancreatic Cancer


Phase 2
18 Years
90 Years
Not Enrolling
Both
Pancreatic Cancer

Thank you

Trial Information

Phase II Study to Evaluate the Efficacy of Trilogy Stereotactic Body Radiotherapy (SBRT) for Pancreatic Cancer


Inclusion Criteria:

- Pancreatic tumors not to exceed 10 cm in greatest axial dimension

- Histologically confirmed malignancies of the pancreas

- Unresectable by CT criteria or exploratory laparotomy or laparoscopy

- Patients with metastatic disease may be treated if they are symptomatic from the
primary tumor

- ECOG status of 0, 1, or 2

- No chemotherapy two weeks prior or two weeks following radiosurgery

Exclusion Criteria:- Patients without pancreatic cancer

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall survival and quality of life

Outcome Time Frame:

unknown

Safety Issue:

No

Principal Investigator

Albert Koong

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Institutional Review Board

Study ID:

PANC0005

NCT ID:

NCT00350142

Start Date:

December 2004

Completion Date:

October 2008

Related Keywords:

  • Pancreatic Cancer
  • Pancreatic Neoplasms

Name

Location
Stanford University School of Medicine Stanford, California  94305-5317